Wells Fargo initiated coverage of Revolution Medicines (RVMD) with an Overweight rating and $67 price target The firm believes daraxonrasib’s mechanism of action is “de-risked” in pancreatic ductal adenocarcinoma and second-line non-small cell lung cancer. A positive readout for the RASolute302 trial, expected in 2026, is a high probability, the analyst tells investors in a research note. Wells likes the setup for Revolution shares over the next 12-18 months.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating
- Revolution Medicines’ Earnings Call: Progress Amid Challenges
- Optimistic Outlook for Revolution Medicines Amid Strategic Developments and Pipeline Progress
- Revolution Medicines Advances RAS-Targeted Therapies
- Revolution Medicines reports Q2 EPS ($1.31), consensus ($1.12)